These results demonstrate that HSPC-mediated lentiviral gene therapy using LV-IGF2.GAAco is able to achieve full correction of glycogen accumulation and pathology in murine Pompe disease. This evidence concerns the gene IGF2 and Glycogen storage disease due to acid maltase deficiency.